The study was performed on 20 couples samples of nasopharyngeal carcinoma patients in K hospital in Hanoi. The findings indicated that: the prevalence of LMP1-EBV gene in peripheral blood of healthy persons was 96.7% (29/30 positive cases); the prevalence of LMP1-EBV gene in 20 UCNT nasopharyngeal carcinoma patients was 100% (20/20 positive cases); the prevalence of LMP1-EBV gene in 20 patients with other head and neck tumors was 100% (5/5 positive cases). On electrophoresis, 90% biopsies of nasopharyngeal carcinoma patients had deletion in LMP1 gene, while LMP1-EBV gene in peripheral blood of these patients, there were only 10% having deletion mutations.
Neoplasms ; diagnosis ; Mutation ; Genes ;

The role of suppression of small RNA molecules in the management of malignity and viral infection on human was studies and discussed. SiRNA (small interference RNA) suppressing gene expression was described. In the year 2001, Ribopharma AG researchers had first demontrated the function of RNAi in mammal cells. SIRPLEX is appropriate with target gene, for using in the treatment of suppression of pathological gene in various genera, including human.
RNA ; Genes ; Gene Silencing

Cell’s development is divided two phase: growth and differentiation to mature cell with different biological functions and then death. There is a balance between growth and death to maintain the endothelial balance. The disorder of this balance can cause the malignant diseases. The immortality is the most important property of malignant cells, not for normal cells. The tumor suppressive genes include gene P53; gene P21 cip1 gene P 300/CBP, gene BTG 2 and gene P73. Genes play role of repaire of damaged DNA include RM, RPA, BRCA1 and BRCA2. The lost telomerase or inhibition of telomerase will exclude the tumor cells.
neoplasms ; Cell Growth Processes

Background: Primary nephrotic syndrome in adult patients is a common sign of patients with primary glomerular disease. Objective: To evaluate the responsiveness of adult patients with primary nephrotic syndrome to corticosteroid alone or in combination with cyclophosphamid and the treatment - related complications. Subjects and method: Based on pathological findings 91 patients with primary nephrotic syndrome divided into 2 groups: group 1 (75 patients) were assigned to receive corticosteroid alone at 1 mg/kg/day, group 2 (16 patients) were assigned to receive the corticosteroid at 0.5 mg/kg/day and cyclophosphamid at 2 mg/kg/day. 11 non - responders from group 1 were switched to group 2 after 6 months of treatment by \r\n', u'corticosteroid alone. The response to therapy was assessed after 3 months and 6 months of treatment. Results:In group 1 the number of patients responding to corticosteroid alone was increasing from 38 after 3 months to 50 after 6 months. In group 2 the number of patients responding to combined protocol was increasing from 4 (14.8%) to 12 (44.4%). The most frequently seen corticosteroid - related complication was cushingoid which is reversible after reducing dose or stop treatment. Severe complications were not common. For the whole group taking cyclophosphamid leucocytopenia, was seen in 4/27 (14.8%) patients, in subgroup of women hypo - amenorrhea was observed in 3/15 (20%) of cases. Conclusions: Results of study encourage the prolongation of treatment. Sterility and if possible preventive measures should be taken into consideration when cyclophosphamid is selected for young patients in reproductive age.\r\n', u'
Nephrotic Syndrome/ therapy